Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.51 |
| ▸ | CAPN1 | P07384 | 1/20 | 0.49 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | GAA | P10253 | 1/20 | 0.46 |
| ▸ | CTSS | P25774 | 5/20 | 0.44 |
| ▸ | CTSK | P43235 | 5/20 | 0.44 |
| ▸ | CA1 | P00915 | 1/20 | 0.44 |
| ▸ | CA2 | P00918 | 1/20 | 0.44 |
| ▸ | CA7 | P43166 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 1/20 | 0.43 |
| ▸ | GLS | O94925 | 1/20 | 0.41 |
| ▸ | MAOA | P21397 | 1/20 | 0.40 |
| ▸ | MAOB | P27338 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22979065 | 1.00 | TDP1 (0.57) | TDP1KMT2ACAPN1PTGS1KCNH2 | |
| SCHEMBL13165128 | 0.97 | TDP1 (0.58) | TDP1KMT2ACAPN1PTGS1KCNH2 | |
| SCHEMBL13165125 | 0.97 | TDP1 (0.58) | TDP1KMT2ACAPN1PTGS1KCNH2 | |
| SCHEMBL13112935 | 0.93 | TDP1 (0.65) | TDP1KMT2ACAPN1PTGS1KCNH2 | |
| SCHEMBL13112915 | 0.93 | TDP1 (0.65) | TDP1KMT2ACAPN1PTGS1KCNH2 | |
| SCHEMBL14737622 | 0.90 | KMT2A (0.53) | TDP1KMT2ACAPN1MEN1GAA | |
| SCHEMBL5741383 | 0.90 | KMT2A (0.53) | TDP1KMT2ACAPN1MEN1GAA | |
| SCHEMBL28969945 | 0.90 | KMT2A (0.53) | TDP1KMT2ACAPN1MEN1GAA | |
| SCHEMBL25118682 | 0.88 | CAPN1 (0.52) | TDP1KMT2ACAPN1MEN1GAA | |
| SCHEMBL10705302 | 0.88 | CAPN1 (0.52) | TDP1KMT2ACAPN1MEN1GAA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8835602-B2 | Templates for nucleation and propagation of peptide secondary structure | INDIAN INSTITUTE OF SCIENCE (IN) | 2014-09-16 | — | — | US | disclosed |
| US-7759357-B2 | Phenylpyrimidine amines as IgE inhibitors | NOVARTIS AG (CH) | 2010-07-20 | — | — | US | disclosed |
| EP-1474146-B1 | PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS | NOVARTIS AG (CH) | 2008-08-27 | — | — | EP | disclosed |
| US-20070281956-A1 | Phenylpyrimidine amines as IgE inhibitors | NOVARTIS AG (CH) | 2007-12-06 | — | — | US | disclosed |
| US-20050119255-A1 | Phenylpyrimidine amines as ige inhibitors | BULUSU MURTY (AT) | 2005-06-02 | — | — | US | disclosed |
| EP-1474146-A1 | PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS | Novartis AG (CH) | 2004-11-10 | — | — | EP | disclosed |
| WO-2003063871-A1 | PHENYLPYRIMIDINE AMINES AS IGE INHIBITORS | NOVARTIS AG (CH) | 2003-08-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070281956-A1 | Phenylpyrimidine amines as IgE inhibitors | FCER2, SELP, FCGR2A | TDP1 2493/4885KMT2A 602/4885CAPN1 3224/4885 |
| US-20050119255-A1 | Phenylpyrimidine amines as ige inhibitors | FCER2, SELP, FCGR2A | TDP1 2493/4885KMT2A 602/4885CAPN1 3224/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.